Original ArticleIndian Journal of Pharmaceutical Education and ResearchVol. 56 | Issue 3 | 2022 | pp. 804–809Open access
Study on the Effect of Phaseolus vulgaris Methanol Extract on Haloperidol and Tacrine Induced Parkinsonism
- 1*,
- 1
- 1 Department of Chemistry, Institute for Excellence in Higher Education, Bhopal, Madhya Pradesh, INDIA.
Published in Indian Journal of Pharmaceutical Education and Research
Correspondence: Balvinder Kaur
Department of Chemistry, Institute for Excellence in Higher Education, Bhopal, Madhya Pradesh, INDIA.
Email: balvinderkaur988@gmail.com
Copyright: © 2022 Manuscript Technomedia. This is an open access article.
- Published:
- Jan 1, 2022
- Received:
- Jul 7, 2021
- Accepted:
- May 16, 2022
- DOI:
- 10.5530/ijper.56.3.131
How to cite
Kaur, B., & Saxena, J. (2022). Study on the Effect of Phaseolus vulgaris Methanol Extract on Haloperidol and Tacrine Induced Parkinsonism. Indian Journal of Pharmaceutical Education and Research, 56(3), 804–809. https://doi.org/10.5530/ijper.56.3.131
Abstract
Background: Parkinson’s disease is neurodegenerative disease with no cure till now, there are treatments that can be explored to ease the symptoms of this disease, and using plant extract we explore the possibility of neutralizing the adverse symptoms and providing better quality of life to patients. Purpose: To demonstrate Anti-parkinson’s activity of Phaseolus vulgaris methanol pod extract by using behavioural models in Wister Albino rats. Materials and Methods: Animals were given Phaseolus vulgaris methanol extract (PVME) prior Haloperidol and Tacrine induced Parkinsonism. Results: Phaseolus vulgaris, family (Leguminosae) is a plant, well known for its Traditional and Ayurvedic application for the treatment of various diseases. In the present studies, Phaseolus vulgaris pods were used to evaluate its Antiparkinson’s activity in behavioral models in Albino rats. The models used here were Haloperidol-induced catalepsy and Tacrine-induced vacuous jaw movement. Phaseolus vulgaris methanol extract (PVME) of 200 and 400 mg/kg were given to rats prior to inducing Catalepsy. Haloperidol, an Antipsychotic drug that induces motor symptoms like Parkinson’s disease, PVME administration for 5 days, and on last day Haloperidol (1mg/kg i.p) was given and catalepsy was observed, it was seen that PVME reduces catalepsy score in a dose-dependent manner. Behavioral parameters also observed using Tacrine, which is an Anticholesterase drug induces chewing movements and orofacial bursts. The results were noted for a duration of 1 hr and found that PVME 400 mg/kg dose significantly reduces the movements and bursts as compared to 200 mg/kg dose. The given results were found close to the standard group (levodopa + carbidopa). Conclusion: The study conducted on Phaseolus vulgaris plant pod extract demonstrates the Neuroprotective activity of plant and its effectiveness to assess the symptoms of Parkinson’s disease. Antiparkinson’s effect of PVME shown to treat symptoms of motor dysfunction attributed to its tendency to reduce oxidative stress and having phenolic content.
Keywords
Subject
Article metadata
| Title | Study on the Effect of Phaseolus vulgaris Methanol Extract on Haloperidol and Tacrine Induced Parkinsonism |
|---|---|
| Authors | Balvinder Kaur; Jyoti Saxena |
| Affiliations | Department of Chemistry, Institute for Excellence in Higher Education, Bhopal, Madhya Pradesh, INDIA. |
| Corresponding author | balvinderkaur988@gmail.com |
| Journal | Indian Journal of Pharmaceutical Education and Research |
| Volume / Issue | Vol. 56, Issue 3 (2022) |
Also in this issue
- Dose Conversion Between Animals and Humans: A Practical Solutionpp. 600–607
- Strategies for the Suitability of Self-assembled Supramolecular Polymersomes in Drug Delivery and Diagnosticspp. 608–617
- Design of Skill Enhancement Module for Pharmacy Students - Need of the Hourpp. 618–627
- Therapeutic Approaches of Nanotechnology for Epileptic Seizures: A Comprehensive Review of Current Knowledgepp. 628–635
- Interstitial Cystitis-Critical Assessment of Current Treatment and Opportunities for Nanodeliverypp. 636–645